5-氟尿嘧啶修饰卟啉的合成及抗肿瘤活性

合成了一种5-氟尿嘧啶修饰的自由卟啉(5-[2-(5-氟尿嘧啶-3-基)乙氧基苯基]-10,15,20-三(4-甲氧基苯基)卟啉)及其2种金属卟啉配合物:5-[2-(5-氟尿嘧啶-3-基)乙氧基苯基]-10,15,20-三(4-甲氧基苯基)锰卟啉和5-[2-(5-氟尿嘧啶-3-基)乙氧基苯基]-10,15,20-三(4-甲氧基苯基)锌卟啉。 通过紫外可见光谱(UV-Vis)、红外光谱(IR)和核磁共振谱氢谱(¹H NMR)对目标化合物进行了结构表征。 用噻唑蓝法(MTT法)测定了自由卟啉、锰卟啉及锌卟啉分别对肺腺癌细胞株A549、肝癌细胞株Bel7402和人结肠癌细胞株HCT-8的抑制活性。 其中,锰卟啉对人结肠癌细胞株HCT-8的半抑制浓度为IC₅₀为17.8 mg/L,具有一定的细胞毒作用。     

新型间氯苯基卟啉-5-氟尿嘧啶化合物的合成与表征

用5-[3-(3-溴丙氧基)苯基]-10,15,20-三(3-氯苯基)卟啉或5-[3-(4-溴丁氧基)苯基]-10,15,20-三(3-氯苯基)卟啉与5-氟尿嘧啶反应,合成了1,3-二[5-(3-丙氧基苯基)-10,15,20-三(3-氯苯基)卟啉]-5-氟尿嘧啶(A1)、1-[5-(3-丙氧基苯基)-10,15,20-三(3-氯苯基)卟啉]-5-氟尿嘧啶(B1)、1,3-二[5-(3-丁氧基苯基)-10,15,20-三(3-氯苯基)卟啉]-5-氟尿嘧啶(A2)、1-[5-(3-丁氧基苯基)-10,15,20-三(3-氯苯基)卟啉]-5-氟尿嘧啶(B2),产率分别为20.4%、12.3%、21.4%、11.4%。通过红外光谱、紫外可见光谱、核磁共振谱和基质辅助激光解吸-电离飞行时间质谱测试技术表征了其结构。对目标化合物的合成分离纯化条件进行了研究。结果表明,选择DMF为溶剂,反应温度在120℃,反应时间10h,产率较高;采用硅胶G(粒径40μm)柱层析,按试验产品量,柱子直径为3cm,柱高10cm,用V(氯仿)∶V(丙酮)=15∶1为洗脱剂,分离效果较好。     

5-[2-(对苯偶氮苯氧基)丁氧基]苯基-10,15,20-三[(对甲氧基苯基)]卟啉及其金属配合物的合成

以5-[2-(4-溴丁氧基)苯基]-10,15,20-三(对甲氧基苯基)卟啉和对羟基偶氮苯为原料,经取代反应合成新化合物5-[2-(对苯偶氮苯氧基)丁氧基]苯基-10,15,20-三[(对甲氧基苯基)]卟啉(2),2经配位反应合成了金属铜,锌配合物(2a)和(2b),其结构经UV-Vis,1H NMR,IR和元素分析表征。     

新型桥连双卟啉化合物的合成及结构表征

通过将4,4′-二羧基-2,2′-联吡啶、2,6-二溴甲基吡啶、2,6-二羟甲基吡啶和1,8-二氨基萘分别与5-(4-羟基苯基)-10,15,20-三苯基卟啉(1a)、5-(4-甲酰苯基)-10,15,20-三苯基卟啉(1b)和5-[4-(4′-溴代丁氧基)苯基]-10,15,20-三苯基卟啉(1c)反应,合成了3类新型的双卟啉化合物2a-2e,经IR,¹HNMR,MS,UV-Vis光谱及元素分析对中间体和目标化合物的结构进行了表征.     

哌嗪取代卟啉的合成、表征及其抗癌活性

设计并合成了6个具有抗癌活性的哌嗪取代卟啉化合物,分别为5,10,15,20-四[4-(4'-乙基哌嗪基)苯基]卟啉(TEPPH2,8a),5,10,15,20-四[4-(4'-丁基哌嗪基)苯基]卟啉(TBPPH2,8b),5,10,15,20-四[4-(4'-庚基哌嗪基)苯基]卟啉(THPPH2,8c),5,10,15,20-四[4-(4'-苯基哌嗪基)苯基]卟啉(TPhPPH2,8d),5-[4-(4'-乙基哌嗪基)苯基]-10,15,20-三苯基卟啉(EPTPPH2,8e)和5-[4-(4'-丁基哌嗪基)苯基]-10,15,20-三苯基卟啉(BPTPPH2,8f).这些卟啉化合物都由取代苯甲醛与吡咯缩合而成,每一个卟啉分子中含有一个或四个具有抗癌活性的取代哌嗪结构,结构经元素分析,MS,1H NMR,IR和UV-vis等表征.初步的生物活性研究表明,这些化合物具有一定的抗癌活性,因而在医学上可能具有潜在应用前景.     

尾式5-{2-[1-（2-吡啶偶氮）-2-萘氧基]丁氧基苯基}-10，15，20-三对氯苯基卟啉及其Pd^2＋配合物的合成

合成了新的尾式5-{2-[1-(2-吡啶偶氮)2-萘氧基]丁氧基苯基}-10,15,20-三对氯苯基卟啉及其钯配合物,其结构经UV,1H NMR,IR及元素分析表征.     

新型氯苯基卟啉-5-氟尿嘧啶的合成

以3,4-二氯苯甲醛、对羟基苯甲醛,吡咯和1,5-二溴戊烷(或1,6-二溴己烷)为原料,经两步反应合成了溴烷氧基氯苯基卟啉(2a或2b);2与5-氟尿嘧啶反应,合成了两种新型的氯代苯基卟啉-5-氟尿嘧啶[1a(产率28.26%)和1b(产率29.34%)],其结构经UV-Vis,~1H NMR,IR和MS表征.     

酪氨酸修饰新型手性卟啉配合物的合成与表征

利用亲核取代反应合成了一种L-酪氨酸修饰的新型手性自由卟啉(5-[2-(L-酪氨酸)乙氧基苯基]-10,15,20-三苯基卟啉)及其对应的金属锌卟啉(5-[2-(L-酪氨酸)乙氧基苯基]-10,15,20-三苯基锌卟啉).通过元素分析、紫外-可见光谱、核磁共振氢谱、圆二色谱、红外光谱、荧光光谱等多种谱图对合成的目标化合物进行了表征.     

5-氟尿嘧啶卟啉锰/锌配合物的合成、光电性质及抗癌活性

合成了新型5-氟尿嘧啶修饰的自由卟啉5-(2-(5-氟尿嘧啶-3-基)乙氧基苯基)-10,15,20-三苯基卟啉(L)及其锰配合物(MnL)和锌配合物(ZnL)。通过紫外-可见光谱、红外光谱、核磁共振氢谱及高分辨质谱等手段进行了结构表征。研究了它们的荧光性质和电化学性质;应用标准磺酰罗丹明B法(SRB法)测试了目标化合物对人肺癌细胞株A549、人肝癌细胞株Bel-7402和人结肠癌细胞株HCT-8生长的抑制活性。结果表明:相同实验条件下,不同金属离子对配合物的荧光强度存在较大影响:锌配合物具有荧光猝灭的性质,而锰配合物未能观察到明显的荧光发射光谱;与自由卟啉和锌配合物相比,锰配合物除卟啉环发生氧化还原反应外,Mn~(2+)自身也发生了氧化还原反应;抗癌活性测试显示锰配合物较其他2种化合物有较好的抗癌活性。     

新型离子型尾式乙基咪唑基卟啉化合物的合成与表征

通过不对称的单羟基卟啉化合物、二溴烷烃、咪唑和溴乙烷反应,合成了一种新型的离子型尾式卟啉化合物——溴化5-对{4-[1-(3-乙基)-咪唑基]丁氧基}苯基-10,15,20-三苯基卟啉(Et-ImBPTPP)Br,并采用质谱、紫外光谱、红外光谱、热重分析、元素分析、能谱和核磁共振氢谱对该化合物进行了结构表征。     

烟酸-卟啉二元化合物的合成、表征及其电化学性质

通过亲核取代反应合成了3个新的烟酸-卟啉二元化合物, 并用红外光谱、紫外-可见光谱、核磁共振氢谱、元素分析和质谱对化合物的结构进行确认, 通过循环伏安法研究了其电化学性质.     

Synthesis and different substituent effects on spectral and electrochemical properties of porphyrin nicotinic acid binary compounds

The porphyrin nicotinic acid binary compounds with different substituents in porphine rings (5-(4-nicotinicoxyldecyloxy)phenyl-10,15,20-triphenylporhyrin 2a, 5-(4-nicotinicoxyldecyloxy)phenyl-10,15,20-tri(4-chlorophenyl)porphyrin 2b and 5-(4-nicotinicoxyldecyloxy)phenyl-10,15,20-tri(4-methoxyphenyl)porphyrin 2c) were synthesized. All of them have been characterized, assigned and analyzed by UV–vis, IR, MS and ¹H NMR spectra. Their electrochemical and spectroscopic properties were studied by using cyclic voltammetry, fluorescence spectra and Resonance Raman spectra. Different substituents have a little influence on electrochemical behavior and fluorescence spectra. In the Resonance Raman spectra, the substituent has little influence on the skeleton vibration of porphyrin and has much influence on the vibration of phenyl.     

1H NMR investigation of high-spin and low-spin iron(III) meso-ethynylporphyrins

The 1H NMR spectra of iron(III) 5-ethynyl-10,15,20-tri(p-tolyl)porphyrin [(ETrTP)Fe(III)X(n)], iron(III) 5-(phenylethynyl)-10,15,20-tri(p-tolyl)porphyrin [(PETrTP)Fe(III)X(n)], iron(III) 5-(phenylbutadiynyl)-10,15,20-tri(p-tolyl)porphyrin [(PBTrTP)Fe(III)X(n)], iron(III) 5,10,15,20-tetra(phenylethynyl)porphyrin [(TPEP)Fe(III)X(n)], iron(III) 1,4-bis-[10,15,20-tri(p-tolyl)porphyrin-5-yl]-1,3-butadiyne {[(TrTP)Fe(III)X(n)]2 B}, and 5,10,15-triphenylporphyrin [(TrPP)Fe(III)X(n)] have been studied to elucidate the impact of meso-ethynyl substitution on the electronic structure and spin density distribution of high-spin (X = Cl-, n = 1) and low-spin (X = CN-, n = 2) derivatives. The meso substituents, i.e., ethynyl, phenylethynyl, and phenylbutadiynyl, provided insight into the efficiency of spin density delocalization along structural elements that are typically applied to transmit electronic effects along multipart polyporphyrinic systems. The positive spin density localized at the meso-carbon of high-spin iron(III) ethynylporphyrins is effectively delocalized along the ethyne or butadiyne fragment as illustrated by the comparison of isotropic shifts of C(meso)-H and -CC-H determined for (TrPP)Fe(III)Cl (-82.6 ppm, 293 K) and (ETrTP)Fe(III)Cl (-49.5 ppm, 298 K). The replacement of the ethynyl hydrogen by phenyl or phenylethynyl provided evidence for the pi spin density distribution around the introduced phenyl ring. An analysis of the isotropic shifts for the low-spin bis-cyanide iron(III) porphyrins series reveals the analogous mechanism of spin density transfer. Treatment of high-spin [(TrTP)Fe(III)Cl]2 B with a base resulted in formation of the cyclic [(TrTP)Fe(III)OFe(III)(TrTP)B]2 complex linked by two mu-oxo bridges. (TPEP)H2 has been characterized by X-ray crystallography as a porphyrin dication where two molecules of trifluoroacetic acid associate with two coordinated trifluoroacetate anions. The X-ray structure of bis-tetrahydrofuran 1,4-bis[10,15,20-tri(p-tolyl)porphyrinatozinc(II)-5-yl]-1,3-butadiyne complex {[(TrTP)Zn(II)(THF)]2 B} reveals two parallel, non-coplanar [(TrTP)Zn(THF)] subunits linked by the linear butadiyne moiety.     

四(5-氟尿嘧啶-1-基乙酰氧基苯基）卟啉及其锌配合物的合成

以二环己基碳二亚胺为脱水剂,meso-四(对羟基苯基)卟啉与5-氟尿嘧啶-1-基乙酸反应,合成了一种新型meso-四[4-(5-氟尿嘧啶-1-基乙酰氧基)苯基]卟啉化合物(A),产率12.7%;将其与乙酸锌反应得到其锌配合物(B),产率30.8%。 通过1H NMR、IR、MS、UV-Vis及元素分析确证了卟啉化合物A及其锌配合物B的结构。     

几种取代胡椒醛缩合不对称卟啉化合物的合成及结构表征

利用微波加热法, 以6-硝基胡椒醛、两种R取代苯甲醛(R＝H, Cl)、吡咯为原料, 在丙酸中缩合, 合成了两种新的不对称卟啉化合物5-(2-硝基-4,5-亚甲二氧基)苯基-10,15,20-三苯基卟啉(2)和5-(2-硝基-4,5-亚甲二氧基)苯基-10,15, 20-三对氯苯基卟啉(3). 将2和3还原得到了化合物5-(2-氨基-4,5-亚甲二氧基)苯基-10,15,20-三苯基卟啉(4)和5-(2-氨 基-4,5-亚甲二氧基)苯基-10,15,20-三对氯苯基卟啉(5). 新化合物结构分别经UV-Vis, IR, ¹H NMR及元素分析所证实. 荧光测试表明, 几个化合物都有比较好的荧光强度, 且氨基取代化合物的荧光强度比相应的硝基化合物的大.     

Preparation of 3-(4-chlorophenyl)-2-(2-aminothiazol-4-yl)-5-methoxybenzo[b]furan derivatives and their leukotriene B(4) inhibitory activity

A series of 3-(4-chlorophenyl)-2-(2-aminothiazol-4-yl)benzo[b]furan derivatives 6-10 were prepared and their leukotriene B(4) inhibitory activity was evaluated. We found that several compounds showed strong inhibition of calcium mobilization in CHO cells overexpressing human BLT(1) and BLT(2) receptors. Among them, 3-(4-chlorophenyl)-2-[5-formyl-2-[(dimethylamino)methyleneamino]thiazol-4-yl]-5-methoxybenzo[b]furan 9b showed the most potent and selective inhibition for the human BLT(2) receptor, and its IC(50) value was smaller than that of the selected positive control compound, ZK-158252.     

Synthesis of ferrocenyl-containing heterocyclic derivatives of 5-(4-aminophenyl)-10,15,20-triphenylporphyrin for sonodynamic therapy

The condensation of 1-(ferrocenylalkyl)pyrazole-3-carbaldehydes with 4′-aminotetraphenylporphyrin, followed by reduction with NaBH(OAc)₃ in 1,2-dichloroethane, provides a convenient method for the synthesis of 5-{4-[({1-[1-(ferrocen-1-yl)alkyl]-5-methyl-1H-pyrazol-3-yl}methyl)amino]phenyl}-10,15,20-triphenylporphyrins which exhibit pronounced cytotoxicity against Staphylococcus aureus under ultrasonic irradiation.     

Synthesis and cytotoxic activity of some novel N-pyridinyl-2-(6-phenylimidazo[2,1-b]thiazol-3-yl)acetamide derivatives

A series of novel compounds bearing imidazo[2,1-b]thiazole scaffolds were designed and synthesized based on the optimization of the virtual screening hit compound N-(6-morpholinopyridin-3-yl)-2-(6-phenylimidazo[2,1-b]thiazol-3-yl)acetamide (5a), and tested for their cytotoxicity against human cancer cell lines, including HepG2 and MDA-MB-231. The results indicated that the compound 2-(6-(4-chlorophenyl)imidazo[2,1-b]thiazol-3-yl)-N-(6-(4-(4-methoxybenzyl)piperazin-1-yl)pyridin-3-yl)acetamide (5l), with slightly higher inhibition on VEGFR2 than 5a (5.72% and 3.76% inhibitory rate at 20 μM, respectively), was a potential inhibitor against MDA-MB-231 (IC(50) = 1.4 μM) compared with sorafenib (IC(50) = 5.2 μM), and showed more selectivity against MDA-MB-231 than HepG2 cell line (IC(50) = 22.6 μM).